Esperion Therapeutics, Inc.

NASDAQ:ESPR

Biotechnology

Healthcare
$3.18 -0.32%

+$0.00 today

Market cap
$661.15M
Beta
1.07
P/E (TTM)
-107.3
EPS (TTM)
-$0.03
52W Low $0.95High $4.18

Volume 0.00M

Average 12.29M

ESPR Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Esperion Therapeutics, Inc.NASDAQ: ESPR

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue grows, but more slowly than its trailing trend

Q1 FY2026 cost of revenue of $34.57M rose 9.6% year over year, behind the +62.5% change in trailing-twelve-month cost of revenue. Sequentially, it rose 24.1% from the prior quarter. Over 3 fiscal years it compounded at +68.6% a year.

Context

  • Cost of revenue amounted to 32.1% of revenue in FY2025, up 11.4 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +9.6% toward the trailing-twelve-month pace of +62.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$34.57M+24.1% QoQ
Last fiscal yearDec 2025
$129.22M+88.4% YoY
LTMMar 2026
$146.39M+62.5% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.6%——
1 year+88.4%——
3-year CAGR+68.6%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
129.22M USD
Year-over-year change
+88.4%
4-year CAGR
+73.6%

Cost of Revenue vs competitors

How ESPR compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +62.5% is the 2nd highest of 8, against a peer median of +0.2%.
  • Cost of revenue amounts to 35.0% of revenue for ESPR, versus a peer median of 55.6%.
ESPR Competitors
Cost of Revenue for ESPR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNDLSNDL Inc.LTM Mar 2026CA$682.57M CAD+0.2%+6.3%72.8%
EBSEmergent BioSolutions Inc.LTM Mar 2026$376M USD-38.7%-15.3%55.6%
OFIXOrthofix Medical Inc.LTM Mar 2026$255.74M USD-3.2%+29.9%31.0%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$146.39M USD+62.5%+68.6%35.0%
RGNXREGENXBIO Inc.LTM Mar 2026$87.94M USD+139.2%-28.1%100.1%
SIGASIGA Technologies, Inc.LTM Mar 2026$32.49M USD+15.1%+41.7%34.6%
ABSIAbsci CorporationLTM Mar 2026$26.01M USD-49.9%-41.6%1416.9%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$18.37M USD+7.2%-4.0%36.5%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$306K USD———
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$55K USD———
Peer median (excluding ESPR) —+0.2%-4.0%55.6%

Competitors are the stored peer set for ESPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue78.45M75.48M116.33M332.31M403.14M
Cost of Revenue14.22M26.97M43.27M68.6M129.22M
Gross Profit64.23M48.51M73.07M263.71M273.91M
Gross Margin81.9%64.3%62.8%79.4%67.9%
Research & Development105.98M118.93M86.11M46.24M47.85M
Selling, General & Admin184.99M109.08M142.52M163.07M165.79M
Operating Expenses290.96M228.01M228.63M209.31M213.64M
Depreciation & Amortization612K500K164K63K105K
EBITDA(222.14M)(176.35M)(150.11M)7.57M63.87M
EBITDA Margin-283.2%-233.7%-129.0%2.3%15.8%
Operating Income(226.73M)(179.5M)(155.56M)54.4M60.27M
Operating Margin-289.0%-237.8%-133.7%16.4%15.0%
Interest Income00003.5M
Interest Expense46.35M56.81M58.98M59.25M84.6M
Other Income / Expenses(42.38M)(54.16M)(53.69M)(106.15M)(81.11M)
Income Before Tax(269.11M)(233.66M)(209.25M)(51.75M)(20.84M)
Pre-Tax Margin-343.0%-309.6%-179.9%-15.6%-5.2%
Income Tax Expense00001.84M
Net Income(269.11M)(233.66M)(209.25M)(51.75M)(22.68M)
Net Margin-343.0%-309.6%-179.9%-15.6%-5.6%
EPS (Basic)(11.03)(4.33)(2.03)(0.28)(0.11)
EPS (Diluted)(11.03)(4.33)(2.03)(0.28)(0.11)
Weighted Avg Shares28.9M66.41M103.11M187.18M207.87M
Weighted Avg Shares (Diluted)28.9M66.41M103.11M187.18M207.87M

Esperion Therapeutics, Inc.

NASDAQ:ESPR

Intrinsic Alpha fair value

Locked

Current Price

$3.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.